Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeljanz for cutaneous T cell lymphoma (mycosis fungoides) – open-label pilot study
2022-500599-79-00Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in mycosis fungoides (MF), sponsored by Aarhus University Hospital. Primary endpoint: Overall clinical response assessment. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on 2022-500599-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500599-79-00.